ONL Therapeutics’ Post

Northern Gritstone has led a £4M seed round for Exciting Instruments, with co-investors Empirical Ventures, Praetura Ventures, and serial entrepreneurs Stan Boland and Jonathan Milner Exciting Instruments is transforming single-molecule microscopy, making it accessible beyond specialist labs. Their platform enables high-throughput molecular analysis, driving breakthroughs in drug development, clinical diagnostics, and research. The funding will support team growth, product evolution, and new commercial partnerships, accelerating its impact on global health outcomes. Duncan Johnson, CEO of Northern Gritstone, said: 'This funding validates the incredible deep tech opportunities within the Northern Triangle.' Learn more: https://lnkd.in/eQRMbGvM #DeepTech #Innovation #NorthernGritstone #ExcitingInstruments #FundingNews

✦ DIMENSION CAPITAL has successfully raised $500 million for its SECOND FUND, surpassing its initial target of $400 million and drawing strong investor interest. ✦ The FIRM, established in 2022, concentrates on the INTERSECTION of TECHNOLOGY and LIFE SCIENCES, funding diverse development stages. ✦ Significant INVESTMENTS include CHAI DISCOVERY and ENVEDA BIOSCIENCES, with a focus on AI in DRUG DISCOVERY. #Investments #LifeSciences #TechInnovation

Atlas Venture announces $450 million fund to invest in biotech startups 💰 With a track record spanning over 3 decades, the venture capital (VC) firm is known for collaborating with talented entrepreneurs to found, seed, incubate, and invest in new companies that will bring innovative medicines to patients. This $450M raised from a long-standing group of limited partners (LPs) is the 14th fund for Atlas. Among numerous other portfolio company successes, Disc Medicine; Korro Bio, Inc.; Q32 Bio Inc.; and Third Harmonic Bio have gone public. Is this mammoth fund an indicator of brighter times for biotech in 2025? Check out the full press release from Business Wire here: businesswire [DOT] com/news/home/20241205893482/en/Atlas-Venture-Announces-450-Million-Fund-XIV Image source here: citybiz [DOT] co/article/633698/atlas-venture-closes-450-million-fund-xiv Also, I'm on the hunt for sales or business development opportunities that align with my 10 years in genome engineering, stem cells, and molecular biology. Know of any life science vendors that are hiring in Boston? #venturecapital #biotechnology #opentowork

Fluid Biomed Inc. is pioneering a new approach to the treatment of brain aneurysms through its unique bioabsorbable polymer-based stent technology. The ReSolv™ stent, developed by co-founders and leading academic neurosurgeons John Wong and Alim Mitha has demonstrated functional benefits in a first-in-human clinical study to treat brain aneurysms, a leading cause of stroke and disability. LifeArc Ventures continues to strengthen its focus on ground-breaking medical technology by supporting Fluid Biomed’s Series A financing alongside international investors including Amplitude Ventures, IAG Capital Partners, ShangBay Capital and METIS Innovative.

There's been a lot of online discussion as to why Illumina chose to buy Fluent BioSciences Inc. out of the half dozen similar early stage competitors in the space. The focus of the discussion has been on assay performance but I'm drawn to Fluent's clearest differentiator from its competitors - it's the only one that was an Illumina Ventures investment - what a coincidence 😳 From its founding in 2016 Illumina Ventures (IV) has loudly proclaimed its "independence" from Illumina. But as John Stewart joked the about the Wuhan Institute of Virology "The disease is the same name as the lab. That’s just a little too weird!” And it's not just the name of course: founding partner was an Illumina SVP, and oh yeah Illumina put in maybe half of the $560M funding. Independent my ass 🤣 IMO Illumina shouldn't be buying Illumina Venture investments; it's a situation rife with conflicts of interest as witnessed by GRAIL where Illumina was also buying its own investment. And why poke the FTC? 🤯 Illumina Ventures Exits (you can see why they may want help 🥲):

Fluid Biomed Inc. Raises $27 Million USD in Oversubscribed Series A Financing to Advance World’s First Bioabsorbable Polymer-Based Stent To Treat Brain Aneurysms The company is thrilled to announce the successful close of an oversubscribed $27M USD Series A financing, co-led by Amplitude Ventures and an undisclosed major strategic investor. Funding will be used to advance our ReSolv™ stent, the world’s first bioabsorbable polymer-based stent to treat brain aneurysms, into additional human clinical trials. Fluid Biomed also thanks the many institutional and private investors who helped us reach this milestone, including IAG Capital Partners, LifeArc Ventures, ShangBay Capital, METIS Innovative, Accelerate Fund III managed by Yaletown Partners, Wharton Alumni Angels, Threshold Impact, Thin Air Labs, One Six 8 Ventures, HaloHealth, Bluesky Equities, UCeed Neuro Fund from the University of Calgary UCeed Investment Funds, and Adara Venture Capital. Please read the full press release here: https://bwnews.pr/4fjnycS Note that the ReSolv™ stent is an investigational medical device and not available for routine clinical use or sale.

We are happy to announce that Angel Investors of STAN invested in Denovo Sciences for the second time, marking our 23rd deal. Denovo Sciences is a deep technology company that creates novel therapeutics using state-of-the-art AI technologies. The startup applies Deep Reinforcement Learning (DRL) to address complex challenges in drug discovery. Denovo Sciences was developed as part of the Foundation for Armenian Science and Technology (FAST) Advanced Solutions Center (ASCENT) program. It was a venture builder program where researchers and scientists collaborated on in-depth idea exploration, followed by comprehensive feasibility studies, proof of concept, and later prototype development. Following the ASCENT program, Denovo Sciences has successfully raised pre-seed and seed funding, gaining the trust of investors from Armenia and abroad, including support from Berkeley SkyDeck, Granatus Ventures, Triple S Ventures, SASTIC, EU institutions, and others. The startup has published 8 peer-reviewed articles, contributing innovative findings in the field of drug discovery. In addition to its scientific contributions, Denovo has formed partnerships with leading companies in the biotech sector from the US, UK, Singapore, and Switzerland, accelerating research and drug development. We are excited to continue the support making the second investment and be part of their journey since the early days. Congratulations to Denovo Sciences and STAN Angel Investors on this partnership! #STAN #DenovoSciences #investmentnews #Armeniansartupecosystem #deeptech

We're happy to announce the newest addition to our portfolio - Fluid Biomed Inc. Today they announced their $27M Oversubscribed Series A Financing, co-led by Amplitude Ventures and an undisclosed major strategic investor, to advance the World's First Bioabsorbable Polymer-based Stent to treat Brain Aneurysms. We're proud to announce it was the largest Series A medtech financing in Canada this year and in recent memory! Congratulations to John Wong, Alim Mitha and the rest of the Fluid team on this financing. For our thoughts on the company and why we invested, please see our blog post - https://lnkd.in/g4Ahz3i6 #Medtech #BrainAneurysms #Neurovascular #VentureCapital #Healthcare #AmplitudeVC

We are thrilled for Rutgers research team Nervana Therapeutics to be part of the inaugural Venturium Virtual Showcase, where they will present the technology they developed at Rutgers to an audience of venture capital investors, venture studios, accelerators, incubators, industry partners, and entrepreneurs. Nervana Therapeutics' technology is a cellularized nerve regeneration graft (CNRG) that will speed patient recovery from peripheral nerve injury, improve recovery of sensation and motor function, reduce the need for extra surgeries, and decrease lifetime medical and socioeconomic costs of new and poorly-recovered injuries. Venturium 2024, co-sponsored by Rutgers Research, is a curated showcase highlighting spinouts and technologies from members of the Tech Transfer Venture Consortium (TTVC), including Rutgers and fellow co-sponsors Kentucky Commercialization Ventures, Innovate Carolina, Northeastern University Center for Research Innovation (CRI), and PCI Ventures. This event embodies a movement towards collaborative growth, technological advancement, and revolutionizing access to academic venture opportunities.   #RutgersInnovation #RutgersResearch #venturium24 #techtransfer #techinnovation #techventures #ventureforward #cofounderconnection #collaborativegrowth

Dimension has successfully closed an oversubscribed second fund at $500M, exceeding their initial $400M target. With a unique focus on the crossroads of tech and life sciences, Dimension has backed innovative companies like Chai Discovery and Enveda Biosciences, driving advancements in AI-driven drug discovery. Marina Temkin, CFA | TechCrunch https://lnkd.in/dcgnXv9U #lifesciences